Ambrx - About the company
Ambrx is an acquired company based in San Diego (United States), founded in 2003. It operates as a Developer of Antibody drug conjugates to treat cancers, metabolic disorders and cardiovascular disorders. Ambrx has raised $346M in funding from investors like Fidelity Investments, Glynn Capital and Apposite Capital, with last known valuation of $*****. The company has 3670 active competitors, including 1245 funded and 855 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of Antibody-drug conjugates to treat cancers, metabolic disorders, and cardiovascular disorders. The company has developed Engineered Precision Biologics (EPBs) by using proprietary genetic code technology to produce antibody-drug conjugates (ADCs) and immuno-oncology conjugates (IOCs) for treating cancers. The product pipeline includes ARX788 an anti-HER2 ADC currently being studied in breast cancer, gastric cancer, and other solid tumors, ARX517 for prostate cancer, and more. They have developed immuno-oncology conjugates for NASH, heart failure, and prostate cancer
- Website
- ambrx.com
- Registered Address
- La Jolla, California
Key Metrics
Founded Year
2003
Location
San Diego, United States
Stage
Acquired
Total Funding
$346M in 6 rounds
Latest Funding Round
Last Known Valuation
$***** as on Jan 08, 2024
Investors
Ranked
556th among 3670 active competitors
Annual Revenue
$1M - $10M as on Dec 31, 2022
Employee Count
58 as on Jul 31, 2026
Similar Companies
Exit Details
Acquired by Johnson & Johnson (Jan 08, 2024)
Legal entities associated with Ambrx
Ambrx is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Ambrx, Inc. CIN: 571147346 , United States, Active | Dec 26, 999 | - | 46 (As on Dec 31, 2024) | - |
AMBRX BIOPHARMA INC. CIN: 1836056 , United States, Active | Aug 10, 2023 | $1M - $10M (As on Dec 31, 2022) | - | - |
Ambrx's acquisition details
Ambrx got acquired by Johnson & Johnson on Jan 08, 2024 at an acquisition amount of $*****.
Click here to take a look at Ambrx's acquisition in detail
Sign up to download Ambrx's company profile
Ambrx's funding and investors
Ambrx has raised a total funding of $346M over 6 rounds. Its first funding round was on Oct 2003. Its latest funding round was a Series E round on Nov 09, 2020 for $*****. 6 investors participated in its latest round. Ambrx has 26 institutional investors.
Here is the list of recent funding rounds of Ambrx:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 09, 2020 | 9719322 | Series E | 7546642 | 4242361 | 6468136 | 9742645 |
Aug 04, 2016 | 3579226 | Series E | 3604787 | 1212977 | 5530779 | |
Mar 31, 2009 | 3436399 | Series D | 1349263 | 9097261 |
Access funding benchmarks and valuations. Sign up today!View details of Ambrx's funding rounds and investors
Ambrx's founders and board of directors
Founder? Claim ProfileAmbrx's employee count trend
Ambrx has 58 employees as of Jul 26. Here is Ambrx's employee count trend over the years:
Uncover Ambrx's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Ambrx's Competitors and alternates
Top competitors of Ambrx include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Ambrx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
556th | Ambrx 2003, San Diego (United States), Acquired | Developer of Antibody drug conjugates to treat cancers, metabolic disorders and cardiovascular disorders | $346M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Ambrx's competitors? Click here to see the top ones
Ambrx's Investments and acquisitions
Ambrx has made no investments or acquisitions yet.
Reports related to Ambrx
Here is the latest report on Ambrx's sector:
News related to Ambrx
Filter this list•
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug PricesPR Newswire•Jun 24, 2025•Oncolytics Biotech, Ambrx
•
Biotech Innovators Pick Up Oncology Slack Amidst Public Funding PressurePR Newswire•Jun 20, 2025•Oncolytics Biotech, Ambrx
•
J&J completes $2B acquisition of ADC developer AmbrxSeeking Alpha•Mar 07, 2024•Ambrx, Johnson & Johnson
•
Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law FirmPR Newswire•Feb 13, 2024•Kuehn, Ambrx, Masonite International, CymaBay Therapeutics and 1 other
•
Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZBPR Newswire•Feb 13, 2024•Halper Sadeh, Ambrx, Juniper Networks, Inhibrx and 1 other
•
Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TGANGlobeNewswire•Feb 10, 2024•Halper Sadeh, Transphorm, Juniper Networks, Harpoon Therapeutics and 1 other
•
The M&A Class Action Firm Continues Investigating the Merger – BBAI, PGTI, AMAM, FGHForexTV•Feb 08, 2024•Monteverde, PGT Innovations, Ambrx, FG Group Holdings and 1 other
•
Halper Sadeh LLC Investigates PGTI, FGH, AMAMBenzinga•Feb 07, 2024•Halper Sadeh, PGT Innovations, Fundamental Global, Ambrx
•
The M&A Class Action Firm Continues Investigating the Merger - AMAM, TGAN, CSTR, THRXPR Newswire•Feb 06, 2024•Monteverde, Ambrx, Transphorm, CapStar Bank and 1 other
•
Halper Sadeh LLC Investigates AXNX, AMAM, FGHPR Newswire•Feb 06, 2024•Halper Sadeh, Axonics, Ambrx, Fundamental Global
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Ambrx
Explore our recently published companies
- Alphabet advertising - United Kingdom based, 2009 founded, Unfunded company
- Alsat-M - Skopje based, 2005 founded, Unfunded company
- Foresight Video - Los Angeles based, Public company
- AlphaGraphics Seattle - Seattle based, 1989 founded, Unfunded company
- 42 Consulting - Rivonia based, 2009 founded, Unfunded company
- 416 Software - San Francisco based, 2012 founded, Unfunded company
